类风湿性关节炎的治疗药物研究进展  

Research progress on therapeutic drugs for rheumatoid arthritis

作　　者：王静[1] 赵庆杰 卓小斌 姜云云[3] 叶光明 WANG Jing;ZHAO Qinjie;ZHUO Xiaobin;JIANG Yunyun;YE Guangming(Huzhou Clinical College of Auhui medical University/No.98 Hospital of PLA,Huzhou 230032,China;School of Pharmacy,Naval Medical University,Shanghai 200433,China;No.101 Hospital of PLA,Wuxi 214044,China)

机构地区：[1]安徽医科大学解放军98临床学院,浙江湖州230032 [2]海军军医大学药学院,上海200433 [3]解放军101医院,江苏无锡214044

出　　处：《药学实践杂志》2019年第6期485-490,共6页Journal of Pharmaceutical Practice

摘　　要：类风湿性关节炎(RA)作为一种常见的自身免疫性疾病,临床表现为关节损伤和滑膜炎症。通过阐述临床RA药物的治疗机制和作用靶点,综述了两大类RA药物,包括小分子合成类RA药物和大分子生物RA药物(肿瘤坏死因子α抑制剂、T、B细胞抑制剂、细胞因子受体抑制剂、靶点RANKL生物制剂以及靶点粒细胞-巨噬细胞集落刺激因子生物制剂),通过结合RA病理机制重点对这两大类药物的治疗机制和作用靶点进行阐明介绍,同时概述了治疗类风湿性关节炎的最新治疗靶点,为类风湿性关节炎患者的治疗提供潜在新方向。Rheumatoid arthritis(RA)is a common autoimmune disease characterized by joint damage and synovial inflammation.Two major classes of RA drugs,including small molecule synthetic RA drugs and macromolecular biological RA drugs(TNF inhibitors、B cell inhibitors、T cell inhibitors、IL inhibitors、target RANKL biologics、target GM-CSF biologics)were reviewed in this paper,focusing on the therapeutic mechanisms of these two classes of drugs.In addition the latest therapeutic target for rheumatoid arthritis was also summarized,which provided a potential new direction for the treatment of patients with rheumatoid arthritis.

关 键 词：类风湿性关节炎 治疗药物 生物制药 

分 类 号：R976[医药卫生—药品]